8 Spam-Free Article(s) Found
Sort:
Date
Filter:
7d
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Wednesday’s Close
MRK Merck & Company, Inc. $70.42 $187.28B N/A
Article Searches
Merck's Ebola Vaccine Approved for Use in Four African Countries https://www.fool.com/investing/2020/02/14/mercks-ebola-vaccine-approved-for-use-in-four-afri.aspx?source=iedfolrf0000001 Feb 14, 2020 - The World Health Organization is calling it a milestone in Ebola prevention.
Pharma Stock Roundup: ABBV, AGN Post Q4 Results, Another Alzheimer's Study Fails http://www.zacks.com/stock/news/765605/pharma-stock-roundup-abbv-agn-post-q4-results-another-alzheimers-study-fails?cid=CS-ZC-FT-analyst_blog|stock_roundup-765605 Feb 14, 2020 - AbbVie (ABBV) and Allergan (AGN) announce Q4 results.
Bristol-Myers' (BMY) CAR T Cell Therapy Gets Priority Review http://www.zacks.com/stock/news/765593/bristol-myers-bmy-car-t-cell-therapy-gets-priority-review?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-765593 Feb 14, 2020 - Bristol-Myers' (BMY) BLA for lisocabtagene maraleucel gets Priority Review from the FDA.
Merck's Keytruda Meets PFS Endpoint in Breast Cancer Study http://www.zacks.com/stock/news/763946/mercks-keytruda-meets-pfs-endpoint-in-breast-cancer-study?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-763946 Feb 13, 2020 - Merck's (MRK) immuno-oncology drug, Keytruda, significantly improves progression free survival as first-line treatment for metastatic triple-negative breast cancer patients in a pivotal study.
Top Stock Analyst Reports for Merck, Philip Morris & American Tower http://www.zacks.com/research-daily/762105/top-stock-analyst-reports-for-merck-philip-morris-american-tower?cid=CS-ZC-FT-research_daily-762105 Feb 12, 2020 - Top Stock Analyst Reports for Merck, Philip Morris & American Tower
Merck's Keytruda Helps Treat an Aggressive Form of Breast Cancer https://www.fool.com/investing/2020/02/12/merck-keytruda-triple-negative-breast-cancer-study.aspx?source=iedfolrf0000001 Feb 12, 2020 - Another win for the seeming unstoppable drug -- this time in metastatic triple-negative breast cancer.
Powerful Proof Anyone Can Invest for an Early Retirement - February 11, 2020 http://www.zacks.com/stock/news/760069/powerful-proof-anyone-can-invest-for-an-early-retirement-february-11-2020?cid=CS-ZC-FT-retirement_ideas|secrets_to_an_early_retirement-760069 Feb 11, 2020 - Achieving the financial freedom to retire early is a dream for most, but making that dream a reality isn't as tricky as it sounds. If you are willing to make some serious lifestyle changes and sacrifices, it can be possible.
What's in Store for AstraZeneca (AZN) This Earnings Season? http://www.zacks.com/stock/news/760054/whats-in-store-for-astrazeneca-azn-this-earnings-season?cid=CS-ZC-FT-analyst_blog|earnings_preview-760054 Feb 11, 2020 - AstraZeneca's (AZN) fourth-quarter results are expected to reflect the impact of new drug sales.

Pages: 1

Page 1